Use of anti-secretory medication: a population-based cohort study

Aliment Pharmacol Ther. 2004 Sep 1;20(5):577-83. doi: 10.1111/j.1365-2036.2004.02120.x.


Background: Total use of anti-secretory medication (H2 blockers and proton pump inhibitors) is increasing rapidly, but knowledge of factors related to the increasing use is sparse.

Aim: To describe development in the use of anti-secretory medication between 1993 and 2002 at a population level.

Methods: We extracted data on use of anti-secretory medication (H2-blockers and proton pump inhibitors) and ulcerogenic drugs, demographic data, and data on gastroscopy and endoscopically verified oesophagitis and peptic ulcer diagnoses, from three large population-based databases covering the County of Funen, Denmark 1990-2002 (population 470,000).

Results: Between 1993 and 2002 incidence of first time users was stable at 16.7/1000 persons/year. Total amount of consumed anti-secretory medication increased from 10.5 DDD/1000 persons/day to 25.2 DDD/1000 persons/day. Ninety per cent of the increase was related to long-term use of anti-secretory medication (> or = 180 DDD/patient/year). In 1993 21% of the anti-secretory medication was used by patients with oesophagitis, this increased to 28% in 2002. The proportion of medication used by peptic ulcer patients decreased from 29% in 1993 to 19% in 2002.

Conclusions: Total use of anti-secretory medication increased as a result of more extensive long-term use, and most of the medication was used by patients without diagnosed peptic ulcer or oesophagitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antacids / therapeutic use*
  • Cohort Studies
  • Denmark / epidemiology
  • Female
  • Helicobacter Infections / drug therapy
  • Helicobacter pylori
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Incidence
  • Long-Term Care
  • Male
  • Middle Aged
  • Odds Ratio
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / epidemiology
  • Proton Pump Inhibitors*


  • Antacids
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors